Research Article

Potensi FuMA stem cells, kombinasi fukoidan dan Bone Marrow Stem Cells (BMSCs), sebagai penatalaksanaan mutakhir pada Infark Miokard Akut

Agung Bagus Sista Satyarsa, Sang Ayu Arta Suryantari, Putu Gupta Arya Gumilang, Ni Nyoman Ayu Dewi

Agung Bagus Sista Satyarsa
Program Studi Pendidikan Dokter, Fakultas Kedokteran Universitas Udayana

Sang Ayu Arta Suryantari
Program Studi Pendidikan Dokter, Fakultas Kedokteran Universitas Udayana

Putu Gupta Arya Gumilang
Program Studi Pendidikan Dokter, Fakultas Kedokteran Universitas Udayana

Ni Nyoman Ayu Dewi
Departemen Biokimia, Fakultas Kedokteran, Universitas Udayana. Email: ayu.dewi@unud.ac.id
Online First: April 01, 2019 | Cite this Article
Sista Satyarsa, A., Arta Suryantari, S., Arya Gumilang, P., Ayu Dewi, N. 2019. Potensi FuMA stem cells, kombinasi fukoidan dan Bone Marrow Stem Cells (BMSCs), sebagai penatalaksanaan mutakhir pada Infark Miokard Akut. Intisari Sains Medis 10(1). DOI:10.15562/ism.v10i1.300


Introduction: Acute myocardial infarction (AMI) is the leading cause of death worldwide. One of the causes of high morbidity and mortality is progressive and irreversible nature of the disease and current treatments are still not optimal in resolving these problems. Thus, this paper aims to describe the potential effect of combination of fucoidan and bone marrow stem cells (namely FuMA stem cells) as the novel management of AMI.

Method: The method used in our paper was literature searching by including the keywords of AMI, BMSCs, and fucoidan.

Result: Fucoidan from brown seaweed has shown a great potential effect as anti-inflammatory, anti-coagulant, anti-atherogenic, anti-oxidant, and anti-fibrotic. It limits the infarct area and increases SDF-1, CXCR4 and Akt expression as well as LVEF. However, fucoidan has not been able to regenerate cardiomyocyte cells in AMI. It takes a combination of BMSCs that have been shown to prevent the expansion of infarction area and improve post-infarction function.

Conclusion: Thus, FuMA stem cells hold a great potential novel therapy for AMI. Further studies are needed to unveil the potential of FuMA stem cells in AMI management.

References

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 cause of death, 1990–2013: a systematic analysis for the global burden of disease study 2013.The Lancet. 2015;9963(385):117–71.

Mozaffarian D, et al. Executive summary: Heart Disease and Stroke Statistics 2016 update: a report from the American Heart Association. Circulation. 2016;133: 447–54.

Melissa J, et al. Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease. JACC: Basic to Translational Science. 2017;2(2): 212-26.

Manzo S., L. Louedec, O. Meilhac, Letourneur, J.B. Michel, I. Elmadbouh. Therapeutic potential of Fucoidan in Myocardial Ischemia. J. Cardiovasc. Pharmacol. 2011;626–32.

Sarlon G, et al. Therapeutic effect of Fucoidan-stimulated endothelial colony-forming cells in peripheral ischemia. Journal of thrombosis and haemostasis: JTH. 2012; 10:38-48.

Sanghi, Vinay, et al. Autologous bone marrow concentrate enriched in progenitor cells—An adjuvant in the treatment of acute myocardial infarction. International Journal of the Cardiovascular Academy. 2016;2(2):77-83.

Micheu, Miruna Mihaela; Dorobantu, Maria. Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World journal of stem cells. 2017;9(4):68.

Samanta, Anweshan; Afzal, Muhammad R.; Dawn, Buddhadeb. Bone Marrow Cell Therapy for Ischemic Heart Disease and the Role of Cardiac Imaging in Evaluation of Outcomes. In: Imaging in Stem Cell Transplant and Cell-based Therapy. Springer. 2017;133-52.

Luo, Lan, et al. Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice novelty and significance. Circulation Research. 2017;120(11): 1768-75.

Yong-seok Han, et al. Fucoidan protects mesenchymal stem cells against oxidative stress and enhances vascular regeneration in a murine hindlimb ischemia model. International Journal of Cardiology. 2015;5273(15):30003-6.

Reed, Grant W.; Rossi, Jeffrey E.; Cannon, Christopher P. Acute myocardial infarction. The Lancet. 2017;389(10065): 197-210.

Anderson, Jeffrey L.; Morrow, David A. Acute myocardial infarction. New England Journal of Medicine. 2017;376(21):2053-64.

Ale, M. T., Mikkelsen, J. D., & Meyer, A. S. Important determinants for Fucoidan bioactivity: a critical review of structure–function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds. Marine Drugs. 2011;9(10): 2106–30.

Jun Hee Lee, et al. Fucoidan improves bioactivity and vasculogenic potential of mesenchymal stem cells in murine hind limb ischemia associated with chronic kidney disease. Journal of Molecular and Cellular Cardiology. 2016;(16):30143-2.

Fitton, Janet Helen; Stringer, Damien N.; Karpiniec, Samuel S. Therapies from Fucoidan: an update. Marine drugs. 2015;13(9):5920-46.

Purnama, et al. Fucoidan in a 3D scaffold interacts with vascular endothelial growth factor and promotes neovascularization in mice. Drug delivery and translational research. 2015;5(2):187-97.

Hwang, Pai-An, et al. The in vitro and in vivo effects of the low molecular weight fucoidan on the bone osteogenic differentiation properties. Cytotechnology. 2016; 68(4): 1349-59.

Cahill, Thomas J.; Choudhury, Robin P.; Riley, Paul R. Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics. Nature reviews: Drug discovery. 2017.

Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, Brinchmann JE, Forfang K, Aakhus S. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the astami randomised, controlled study. Heart. 2009; 95:1983–9.

Wohrle J, et al. Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary stem cell therapy in patients with acute myocardial infarction (scami) trial. Clin Res Cardiol. 2013; 102:765–70.

Sürder, Daniel, et al. The effect of bone marrow derived mononuclear cell treatment, early or late after acute myocardial infarction: Twelve months CMR and long-term clinical results. Circulation research. 2016; 116:308639.

Seung Taek Ji, Hyunyun Kim, Jisoo Yun, Joo Seop Chung, and Sang-Mo Kwon. Promising Therapeutic Strategies for Mesenchymal Stem Cell-Based Cardiovascular Regeneration: From Cell Priming to Tissue Engineering. Stem Cells International Hindawi. 2017;(2017):1-13.

Jiang, Can, et al. Short-and Long-term Therapeutic Efficacies of Intravenous Transplantation of Bone Marrow Stem Cells on Cardiac Function in Rats with Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. Chinese Medical Sciences Journal, 2016, 31(3):142-8.

Mura, M., et al. Improving the Cardioprotective and Regenerative Properties of Bone Marrow Derived Mesenchymal Stem Cells Through the Overexpression of IGF1 and BMP2. Cytotherapy. 2016;18(6): S81.


No Supplementary Material available for this article.
Article Views      : 138
PDF Downloads : 57